Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma – diagnostic and prognostic implications

[1]  J. Nesland,et al.  E‐cadherin and α‐, β‐, and γ‐catenin protein expression is up‐regulated in ovarian carcinoma cells in serous effusions , 2000 .

[2]  J. Nesland,et al.  Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. , 2000, Human pathology.

[3]  J. Nesland,et al.  Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions , 2000, Virchows Archiv.

[4]  M. Saegusa,et al.  CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression , 1999, The Journal of pathology.

[5]  A. Berner,et al.  Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies , 1999, Virchows Archiv.

[6]  A. Freedman,et al.  Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  A. Skubitz,et al.  CD44 and β1 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells , 1999 .

[8]  M. Wells,et al.  CD44 is a marker of endocervical neoplasia. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[9]  M. Saegusa,et al.  Down‐regulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumours , 1999, The Journal of pathology.

[10]  J. Ludlow,et al.  CD44 splice variant expression in clear cell carcinoma of the ovary. , 1998, Gynecologic oncology.

[11]  T. Sugino,et al.  Disorderly CD44 gene expression in human cancer cells can be modulated by growth conditions , 1998, The Journal of pathology.

[12]  P. Fetsch,et al.  Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material , 1998, Diagnostic cytopathology.

[13]  Darai,et al.  Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas , 1998, Histopathology.

[14]  S. Cannistra,et al.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. , 1997, Cancer research.

[15]  F. Gudat,et al.  Expression of CD44 and variant isoforms in cervical intraepithelial neoplasia. , 1996, Gynecologic oncology.

[16]  H. Dvorak,et al.  Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. , 1996, The American journal of pathology.

[17]  L. Puls,et al.  Removal of a 130 pound ovarian neoplasm. , 1996, Journal of the South Carolina Medical Association.

[18]  K. Friedrichs,et al.  CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. , 1995, Cancer research.

[19]  O. Dapunt,et al.  Prognostic value of CD44 splice variant expression in ovarian cancer. , 1995, Oncology.

[20]  R. Bardales.  Malignant effusions. A multimodal approach to cytologic diagnosis , 1995 .

[21]  J. Niloff,et al.  Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  P. Herrlich,et al.  Comparison of immunohistochemistry and RT‐PCR for detection of CD44v‐expression, a new prognostic factor in human breast cancer , 1995, International journal of cancer.

[23]  C. Tropé,et al.  The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. , 1995, Gynecologic oncology.

[24]  C. Schwärzler,et al.  CD44 isoforms during differentiation and development , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[26]  T. Springer.  Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[27]  J. Niloff,et al.  Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. , 1993, Cancer research.

[28]  M. Mihm,et al.  Migration of human melanoma cells on hyaluronate is related to CD44 expression. , 1993, The Journal of investigative dermatology.

[29]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Liao,et al.  The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. , 1991, Cancer cells.

[31]  K. Crickard,et al.  In vitro degradation of extracellular matrix by human ovarian carcinoma cells , 1987, Clinical & Experimental Metastasis.

[32]  G. Turner,et al.  Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan , 2004, Clinical & Experimental Metastasis.

[33]  M. P. Martegani,et al.  Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products. , 1999, The American journal of pathology.

[34]  A. Skubitz,et al.  CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. , 1999, The American journal of pathology.

[35]  Gregory B. Jobes,et al.  Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias , 1998 .

[36]  O. Dapunt,et al.  High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. , 1997, British Journal of Cancer.

[37]  C. Kosary.  FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. , 1994, Seminars in surgical oncology.

[38]  P. Kincade,et al.  CD44 and its interaction with extracellular matrix. , 1993, Advances in immunology.